Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 11/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706453 | 0.85 | SCN10A (0.34) | SCN10AKCNH2 | |
| SCHEMBL8762119 | 0.85 | KDM4E (0.39) | KDM4ELMNAHSD17B10 | |
| SCHEMBL2706449 | 0.84 | CYP17A1 (0.32) | SCN10A | |
| SCHEMBL2707318 | 0.83 | KDM4E (0.35) | SCN10AKDM4ELMNAHSD17B10 | |
| SCHEMBL10141032 | 0.83 | TYMS (0.39) | KDM4ENPC1ALDH1A1RAB9ALMNA | |
| SCHEMBL9977000 | 0.83 | CYP17A1 (0.33) | SCN10A | |
| SCHEMBL19521601 | 0.82 | SCN10A (0.31) | SCN10A | |
| SCHEMBL2705896 | 0.82 | SCN10A (0.36) | SCN10ANPC1ALDH1A1PLA2G1BNFKB1 | |
| SCHEMBL2707301 | 0.81 | CYP17A1 (0.34) | SCN10A | |
| SCHEMBL19521613 | 0.78 | NPSR1 (0.34) | SCN10AL3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9546160-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SCN10A 4625/4885KDM4E 3857/4885NPC1 65/4885 |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SCN10A 4625/4885KDM4E 3857/4885NPC1 65/4885 |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SCN10A 4625/4885KDM4E 3857/4885NPC1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.